Company intelligence / Profile preview

Amasa Therapeutics

Boston, Massachusetts, United Statesamasatx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Proof-of-concept for engineered allogeneic cell therapy to eradicate residual brain tumors is well established in mouse models, showing eradication of tumor cells and improved survival. No human clinical data publicly reported as of October 2025.

Therapeutic areas: Oncology
Modalities: Cell therapyBiologic
Industry: Biotech

Partnerships

Lineage Cell Therapeutics (exclusive option agreement for HyStem biomaterial technology)

Beyond the preview

Go deeper on Amasa Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amasa Therapeutics.

Explore the full profile